GATC Health’s Derisq AI, A FICO Score for Drug Development

GATC Health wants to give drug developers a “FICO score” for clinical risk. In this episode, David Wild talks with GATC chief business officer Tyrone Lam about Derisq, an AI‑driven report that simulates human biology to predict a drug candidate’s safety, efficacy, and off‑target risks before the first patient is enrolled. They discuss how GATC’s Operon platform underpins Derisq and the company’s own pipeline, why a Lloyd’s of London syndicate is using the tool to underwrite clinical‑trial insurance, and how investors are leaning on these models to decide which programs to back.